Stage (next event)
Catalyst Info & Data Links
TITLE: ALKS 3831 for Schizophrenia and Bipolar Disorder CRL
Clinical Trial (NCT02873208) A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION
ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. ALKS 3831 is composed of samidorphan, a novel, new molecular entity, co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post